Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience

Am J Hematol. 2018 May;93(5):E123-E125. doi: 10.1002/ajh.25063. Epub 2018 Feb 24.

Authors

Inuk Zandvakili¹, Caitlin B Conboy^{1

2}, Ayed O Ayed², Elizabeth J Cathcart-Rake², Ayalew Tefferi²

Affiliations

¹ Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
² Division of Hematology, Mayo Clinic, Rochester, Minnesota.

PMID: 29417621
DOI: 10.1002/ajh.25063

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antifungal Agents / therapeutic use
Drug Therapy, Combination / methods
Female
Humans
Lymphohistiocytosis, Hemophagocytic / drug therapy*
Nitriles
Pyrazoles / therapeutic use*
Pyrimidines

Substances

Antifungal Agents
Nitriles
Pyrazoles
Pyrimidines
ruxolitinib